• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

    9/2/25 8:00:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VOR alert in real time by email

    CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Adi Osovsky, S.J.D. as General Counsel. Dr. Osovsky brings 17 years of corporate counsel and law firm experience in the biotechnology and pharmaceutical sectors.

    "We are delighted to welcome Adi to Vor Bio at this important stage in our growth," said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board. "Adi's proven experience advising public biopharmaceutical companies on governance, compliance, and strategic transactions makes her an outstanding addition to our leadership team. Her counsel will be invaluable as we advance our late-stage clinical programs and prepare for growth."

    Dr. Osovsky joins Vor Bio from iTeos Therapeutics, where she served as Executive Vice President, Head of Legal & Corporate Secretary. In that role, she led all of the company's corporate legal and compliance activities and oversaw information technology. She previously held senior legal roles at Sarepta Therapeutics, supporting corporate transactions, securities matters, and governance through a period of rapid growth and transformation. Earlier in her career, she was an associate in the Capital Markets practice at Sullivan & Worcester LLP, where she advised biotechnology and pharmaceutical companies on corporate finance, governance, and securities regulation.

    Dr. Osovsky holds an LL.B. from Tel Aviv University and both an LL.M. and an S.J.D. in Securities Regulation from Harvard Law School.

    "I am thrilled to join Vor Bio at such a pivotal time," said Dr. Osovsky. "Vor Bio's mission to transform the treatment of autoimmune diseases deeply resonates with me, and I look forward to partnering with this talented team to advance the company's mission and enable long-term success for patients."

    About Vor Bio

    Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "aim," "anticipate," "can," "continue," "could," "design," "enable," "expect," "initiate," "intend," "may," "on-track," "ongoing," "plan," "potential," "should," "target," "update," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio's statements regarding its development and growth plans and other statements that are not historical fact. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors. These and other risks are described in greater detail under the caption "Risk Factors" included in Vor Bio's most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.

    Media & Investor Contacts:

    Carl Mauch

    [email protected] 

    Sarah Spencer

    [email protected]



    Primary Logo

    Get the next $VOR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VOR

    DatePrice TargetRatingAnalyst
    6/30/2025$3.00Neutral → Buy
    H.C. Wainwright
    7/26/2022$18.00Outperform
    Wedbush
    4/27/2022$6.00Neutral
    Goldman
    12/17/2021$26.00Buy
    HC Wainwright & Co.
    12/3/2021$38.00Outperform
    Robert W. Baird
    12/3/2021$38.00Outperform
    Baird
    12/2/2021$30.00Outperform
    Oppenheimer
    10/19/2021$40.00Market Outperform
    JMP Securities
    More analyst ratings

    $VOR
    SEC Filings

    View All

    Vor Biopharma Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Vor Biopharma Inc. (0001817229) (Filer)

    9/2/25 10:43:08 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by Vor Biopharma Inc.

    8-K - Vor Biopharma Inc. (0001817229) (Filer)

    8/27/25 12:34:47 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by Vor Biopharma Inc.

    8-K - Vor Biopharma Inc. (0001817229) (Filer)

    8/27/25 8:19:09 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VOR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Reprogrammed Interchange Llc bought 38,974,101 shares (SEC Form 4)

    4 - Vor Biopharma Inc. (0001817229) (Issuer)

    1/2/25 7:42:04 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VOR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

    CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Adi Osovsky, S.J.D. as General Counsel. Dr. Osovsky brings 17 years of corporate counsel and law firm experience in the biotechnology and pharmaceutical sectors. "We are delighted to welcome Adi to Vor Bio at this important stage in our growth," said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board. "Adi's proven experience advising public biopharmaceutical companies on governance, compliance, and strategic transactions makes her an outstanding addition to our leadersh

    9/2/25 8:00:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PureTech Health plc – Half-Year Report

    Achieved meaningful progress toward key value inflection points across our diversified portfolio, with multiple programs advancing into or toward late-stage development Launch of Celea Therapeutics continues our proven, capital-efficient model Maintained a strong financial position with $319.6M PureTech level cash, cash equivalents and short-term investments and $319.9M Consolidated cash, cash equivalents and short-term investments as of June 30, 2025; operational runway into 2028 enables flexibility to drive early-stage innovation while evaluating opportunities for capital returns Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST PureTech Health plc (NA

    8/28/25 2:00:00 AM ET
    $PRTC
    $VOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy

    Results reinforce telitacicept's potential across multiple autoimmune diseases Data anticipated to be presented at an upcoming medical conference CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that its collaborator, RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), achieved the primary endpoint in Stage A of a Phase 3 clinical study in China evaluating telitacicept in adults with IgA nephropathy (IgAN). Details of the study results are planned to be presented at an upcoming medical conference. "Telitacicept continues to demonstrate consistent, disease-modifying

    8/27/25 8:00:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Vor Biopharma upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Vor Biopharma from Neutral to Buy and set a new price target of $3.00

    6/30/25 7:56:45 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wedbush initiated coverage on Vor Biopharma with a new price target

    Wedbush initiated coverage of Vor Biopharma with a rating of Outperform and set a new price target of $18.00

    7/26/22 8:25:46 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Goldman initiated coverage on Vor Biopharma with a new price target

    Goldman initiated coverage of Vor Biopharma with a rating of Neutral and set a new price target of $6.00

    4/27/22 6:14:19 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Reed Sarah Burgess

    3 - Vor Biopharma Inc. (0001817229) (Issuer)

    9/8/25 9:19:26 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Reprogrammed Interchange Llc sold $2,767,982 worth of shares (1,407,628 units at $1.97), decreasing direct ownership by 4% to 35,476,939 units (SEC Form 4)

    4 - Vor Biopharma Inc. (0001817229) (Issuer)

    9/5/25 6:51:25 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Reprogrammed Interchange Llc sold $2,848,511 worth of shares (1,417,998 units at $2.01), decreasing direct ownership by 4% to 36,884,567 units (SEC Form 4)

    4 - Vor Biopharma Inc. (0001817229) (Issuer)

    8/29/25 6:05:12 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VOR
    Leadership Updates

    Live Leadership Updates

    View All

    Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

    CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Adi Osovsky, S.J.D. as General Counsel. Dr. Osovsky brings 17 years of corporate counsel and law firm experience in the biotechnology and pharmaceutical sectors. "We are delighted to welcome Adi to Vor Bio at this important stage in our growth," said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board. "Adi's proven experience advising public biopharmaceutical companies on governance, compliance, and strategic transactions makes her an outstanding addition to our leadersh

    9/2/25 8:00:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

    CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Dallan Murray as Chief Commercial Officer, effective immediately. "We're thrilled to welcome Dallan to Vor Bio at this important inflection point," said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board. "His track record of building high-performing commercial organizations and executing successful product launches will be instrumental as we prepare for potential commercialization of telitacicept and shape our broader growth strategy." Mr. Murray brings more than 25 yea

    8/4/25 8:30:53 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

    - New board members bring decades of experience in company building, corporate strategy, commercialization, and business development CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Alexander (Bo) Cumbo and Michel Detheux, Ph.D., to its Board of Directors, effective July 16, 2025. Alexander (Bo) Cumbo currently serves as President and Chief Executive Officer of Solid Biosciences. Prior to that, he was the founding CEO of AavantiBio, a gene therapy company backed by Bain Capital Life Sciences, Perceptive Advisors, and RA Capital. Bo brings m

    7/21/25 8:30:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VOR
    Financials

    Live finance-specific insights

    View All

    Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

    CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the Board of Directors has approved the initiation of a process to explore a range of strategic alternatives aimed at maximizing both near- and long-term shareholder value.   These strategic alternatives could include, among other alternatives, a potential sale of assets of the Company, a potential licensing of assets of the Company, a sale of the Company, a business combination, a merger or other strategic action. The Company

    5/8/25 8:30:15 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

    Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplantTrem-cel + Mylotarg continue to demonstrate engraftment, shielding, and broadened therapeutic windowCompany has received supportive feedback from the FDA regarding a registrational clinical trial design CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced updated clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data, which was presented in a post

    12/9/24 7:30:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies

    Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with significant potential opportunities across oncology, gene therapy, and autoimmune disorders CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic wind

    9/5/24 4:01:00 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Vor Biopharma Inc.

    SC 13G/A - Vor Biopharma Inc. (0001817229) (Subject)

    11/14/24 4:33:50 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Vor Biopharma Inc. (Amendment)

    SC 13D/A - Vor Biopharma Inc. (0001817229) (Subject)

    2/14/24 4:17:24 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Vor Biopharma Inc. (Amendment)

    SC 13G/A - Vor Biopharma Inc. (0001817229) (Subject)

    2/14/24 4:08:06 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care